M. A. Arndt

Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade.

R. Blantz, A. Deng, T. Rieg, 2010, American journal of physiology. Renal physiology.

Ribonucleases and immunoRNases as anticancer drugs.

S. Rybak, S. Dübel, T. Schirrmann, 2009, Current pharmaceutical design.

The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis.

D. Pizzo, E. Parisi, C. Baskerville, 2009, American journal of physiology. Cell physiology.

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme

D. Newton, S. Rybak, X. Ji, 2004, British Journal of Cancer.